Quantcast
Last updated on April 18, 2014 at 8:33 EDT

Latest HeartLight Stories

2014-01-09 08:28:09

Hospital Universitari i Politecnic La Fe in Valencia is First in Country to Use New Technology MARLBOROUGH, Mass., Jan. 9, 2014 /PRNewswire/ -- CardioFocus, Inc., developer of the HeartLight® Endoscopic Ablation System (EAS) for the treatment of atrial fibrillation (AF), announces that its technology is now available in Spain for clinical use. Physicians at Hospital Universitari i Politecnic La Fe in Valencia were the first in the country to offer the innovative catheter ablation...

2013-10-15 08:29:56

Major Achievement Toward U.S. Availability of Single Procedure Treatment for World's Most Common Arrhythmia MARLBOROUGH, Mass., Oct. 15, 2013 /PRNewswire/ -- CardioFocus, Inc., developer of the HeartLight® Endoscopic Ablation System (EAS) for the treatment of atrial fibrillation (AF), today announced that it has concluded enrollment of its U.S. pivotal trial evaluating the HeartLight system, for the treatment of symptomatic paroxysmal AF. The randomized, controlled trial completed...

2013-05-07 08:31:53

Scientific Session Presentations Feature Laser Balloon Ablation as Single Procedure Treatment for Atrial Fibrillation MARLBOROUGH, Mass., May 7, 2013 /PRNewswire/ -- CardioFocus, Inc., developer of the HeartLight® Endoscopic Ablation System for the treatment of atrial fibrillation (AF), announces that clinical experiences with its technology will be included as part of the scientific sessions at Heart Rhythm 2013, the Heart Rhythm Society's 34(th) Annual Scientific Sessions, May...

2013-04-16 08:29:17

Names Paul LaViolette as Executive Chairman and Renny Clark as Chief Financial Officer MARLBOROUGH, Mass., April 16, 2013 /PRNewswire/ -- CardioFocus, Inc., developer of the HeartLight® Endoscopic Ablation System for the treatment of atrial fibrillation (AF), announced today that it has expanded its management team. Paul LaViolette, previously Chairman of the Board, has been named Executive Chairman and Renny Clark has been named Chief Financial Officer and Treasurer. They will...

2013-01-14 02:30:00

MARLBOROUGH, Mass., Jan. 14, 2013 /PRNewswire/ -- CardioFocus, Inc., developer of the HeartLight® Endoscopic Ablation System for the treatment of atrial fibrillation (AF), announces the U.S. pivotal trial evaluating the safety and efficacy of the HeartLight system is approximately half enrolled. The study, initiated in 2012, is on track to complete enrollment this year. HeartLight is the first catheter ablation system to incorporate an endoscope for direct visualization of the beating...

2013-01-10 08:25:25

MARLBOROUGH, Mass., Jan. 10, 2013 /PRNewswire/ -- CardioFocus, Inc., developer of the HeartLight® Endoscopic Ablation System for the treatment of atrial fibrillation (AF), announces that as of late 2012, more than 1,000 clinical cases have been performed worldwide using the HeartLight technology. The company will be hosting an expert symposium to review the clinical application of HeartLight and key observations made during the first 1,000 cases, which will be held the evening of...

2012-02-21 07:01:00

MARLBOROUGH, Mass., Feb. 21, 2012 /PRNewswire/ -- CardioFocus, Inc., developer of the HeartLight® Endoscopic Ablation System (EAS) for the treatment of atrial fibrillation (AF), announces the first patient has been enrolled and treated in the HeartLight EAS U.S. pivotal trial, designed to evaluate the safety and efficacy of the technology in treating symptomatic AF. The 48-year-old patient, one of the nearly three million Americans with AF,[i] had suffered with paroxysmal...